{"disease":{"id":"relapsed-neuroblastoma","name":"relapsed neuroblastoma"},"drugs":{"marketed":[{"drug_id":"naxitamab","indication_name":"Relapsed or Refractory High-Risk Neuroblastoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hu3F8","generic_name":"NAXITAMAB","company_name":"Y-Mabs Therapeutics Inc","drug_phase":"marketed","molecular_target":"","drug_class":"Glycolipid Disialoganglioside-directed Antibody [EPC]","quality_score":53,"revenue":null,"mechanism":"Hu3F8 works by binding to a specific glycolipid on cancer cells, marking them for destruction by the immune system."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07334301","title":"A Multi-Arm, Platform Trial For Relapsed Neuroblastoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":160,"lead_sponsor_name":"University of Birmingham","has_results":false},{"nct_id":"NCT03635632","title":"C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":94,"lead_sponsor_name":"Baylor College of Medicine","has_results":false},{"nct_id":"NCT05650749","title":"GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":45,"lead_sponsor_name":"Stephan Grupp MD PhD","has_results":false},{"nct_id":"NCT06803875","title":"Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":42,"lead_sponsor_name":"Roberto Chiarle","has_results":false},{"nct_id":"NCT07007117","title":"PHOX2B PC-CAR T Cells for Relapsed Neuroblastoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":38,"lead_sponsor_name":"Stephan Grupp MD PhD","has_results":false},{"nct_id":"NCT07502287","title":"Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"Beijing Biotech","has_results":false},{"nct_id":"NCT07444918","title":"Liposomal Irinotecan, Vincristine, Temozolomide, and Anlotinib for R/R Pediatric Solid Tumors","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":33,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT03458728","title":"Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":31,"lead_sponsor_name":"Bayer","has_results":true},{"nct_id":"NCT05562024","title":"TAA06 Injection in the Treatment of Patients With B7-H3-positive Relapsed/ Refractory Neuroblastoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":24,"lead_sponsor_name":"PersonGen BioTherapeutics (Suzhou) Co., Ltd.","has_results":false},{"nct_id":"NCT04023331","title":"67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":21,"lead_sponsor_name":"Clarity Pharmaceuticals Ltd","has_results":false},{"nct_id":"NCT07027748","title":"Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"Steven DuBois, MD","has_results":false},{"nct_id":"NCT02761915","title":"A Phase I Trial of Anti-GD2 T-cells (1RG-CART)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":17,"lead_sponsor_name":"Cancer Research UK","has_results":true},{"nct_id":"NCT04049864","title":"DNA Vaccination Against Neuroblastoma","phase":"EARLY_PHASE1","overall_status":"UNKNOWN","enrollment_count":12,"lead_sponsor_name":"Belarusian Research Center for Pediatric Oncology, Hematology and Immunology","has_results":false},{"nct_id":"NCT05302921","title":"Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":5,"lead_sponsor_name":"Children's National Research Institute","has_results":false},{"nct_id":"NCT03209869","title":"Treatment of Relapsed or Refractory Neuroblastoma and Osteosarcoma With Expanded Haploidentical NK Cells and Hu14.18-IL2","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"University of Wisconsin, Madison","has_results":false},{"nct_id":"NCT03649438","title":"131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"University of Texas Southwestern Medical Center","has_results":false}],"total":16},"guidelines":[],"source":"Drug Landscape verified database"}